Betton M, Livrozet M, Planas D, et al. - Occurrence of humoral response to SARS-CoV-2 is observed within the first weeks after COVID-19. These antibodies exert a neutralizing activity against SARS-CoV-2, researchers herein sought to report on the evolution of these antibodies overtime after COVID-19 as well as their efficiency against novel variants. In this prospective study, they retrieved sera of 107 patients hospitalized with COVID-19 at 3- and 6-months post-infection and evaluated anti-Spike (S) and anti-Nucleocapsid (NP) IgG via performing quantitative neutralization experiments on top of high-throughput serological assays. Per findings, there was a reduction in IgG rates and serological assays became negative. However, these did not imply loss of neutralizing capacity. Patients previously hospitalized for COVID-19 showed a sustained humoral response against the ancestral strain and the D614G, B.1.1.7 and P.1 variants for at least 6 months. Protection was however weaker against the B.1.351 variant.